The systemic treatment of superficial fungus infections in man at last seems a near reality. Although the polyene antibiotics derived from streptomyces were a significant advance in antifungal chemotherapy against the yeast-like fungi, they failed to influence the common dermatomycoses.1 Recent studies demonstrating the influence of serum factors in superficial fungous infections illustrated the importance of blood-borne substances in confining cutaneous invasion by dermatophytes.2,15 Gentles' recent report of the successful oral treatment of Trichophyton and Microsporum infections in guinea pigs with griseofulvin, a product of several penicillia, was a great step forward.7 Subsequently, Lauder and O'Sullivan found it effective by mouth in calves with Trichophyton verrucosum infections.11 Our paper is a preliminary report of observations on the effectiveness of oral griseofulvin therapy in man.
Griseofulvin is a colorless, neutral, thermostable antibiotic isolated from Penicillium griseofulvin by Oxford, Raistrick, and Simonet,
BLANK H, ROTH FJ, Bruce WW, Engel MF, Smith JG, Zaias N. The Treatment of Dermatomycoses with Orally Administered Griseofulvin. AMA Arch Derm. 1959;79(3):259–266. doi:10.1001/archderm.1959.01560150001001
Customize your JAMA Network experience by selecting one or more topics from the list below.